Beyond the Surface: How Creative Biolabs Accelerates Complement-Targeted Drug Discovery

Creative Biolabs advances complement therapeutic research through high-precision assays and custom microfluidic fabrication, accelerating drug validation timelines.

SHIRLEY, NY, March 24, 2026 /24-7PressRelease/ — The landscape of immunology is undergoing a significant paradigm shift as the complement system moves from the periphery to the center of drug development. Once considered a secondary component of the innate immune response, the complement cascade—a complex network of over 30 proteins—is now a primary target for treating a diverse range of conditions, from rare hematological disorders to widespread neurodegenerative diseases. Creative Biolabs, a specialist in immunology-based drug discovery, has announced its comprehensive solutions designed to address the specific bottlenecks in the development of complement therapeutics.

A primary trend in this evolution is the move away from broad, non-specific pathway screenings toward high-resolution functional analysis. Historically, researchers relied on general assays that provided only a binary view of complement activation. However, modern drug discovery demands a more granular understanding of target engagement.

This has led to the wider implementation of the individual complement component activity assay. By isolating the functional integrity of specific proteins such as C1q, C3, or Factor B, Creative Biolabs allows developers to pinpoint the exact site of therapeutic intervention. This level of detail is essential for verifying that a drug candidate not only hits its target but also preserves the necessary immune functions of non-targeted pathways.

As complement therapeutics move into global, multi-center clinical trials, the reproducibility of data has become a critical bottleneck. Creative Biolabs has refined its methodology for the individual complement component activity assay. This specialized testing allows researchers to measure the functional capacity of discrete proteins within the cascade, providing the high-resolution data necessary to confirm target engagement and drug efficacy during early-stage development.

To support high-throughput environments, Creative Biolabs’ solutions are engineered for seamless integration. “Our complement assay kits are compatible with most automated laboratory platforms. We provide detailed protocols optimized for common automated systems, including specific parameters for liquid handling and incubation steps,” said a scientist from Creative Biolabs.

In addition, Creative Biolabs provides end-to-end customization and fabrication for microfluidic systems. Their advanced manufacturing processes ensure high-precision results, allowing for the development of custom-engineered chips that align with rigorous experimental protocols. By testing drug candidates within these biomimetic environments, researchers can gain predictive insights into how a therapy will perform in the human body, significantly reducing the risks associated with the transition to in vivo studies.

Through these enhanced capabilities, Creative Biolabs continues to support the global pharmaceutical industry in navigating the complexities of the complement system.

Learn more, please visit https://www.creative-biolabs.com/complement-therapeutics/.

About Creative Biolabs
Creative Biolabs is a global biotechnology company at the forefront of providing integrated solutions for complex drug discovery. With a specialized focus on the complement system and micro-engineering technologies, the company provides a comprehensive suite of services, including specialized assays and custom fabrication.

—
For the original version of this press release, please visit 24-7PressRelease.com here